Successful treatment of eosinophilic fasciitis with the anti-IL5 receptor monoclonal antibody benralizumab

Clin Exp Rheumatol. 2023 Mar;41(3):763-764. doi: 10.55563/clinexprheumatol/oxy3ip. Epub 2023 Jan 2.

Authors

Chiara Rizzo¹, Lidia La Barbera¹, Federica Camarda¹, Giulia Maria Destro Castaniti¹, Elisabetta Orlando², Giuliana Guggino³

Affiliations

¹ Rheumatology Section, Internal Medicine and Medical Specialties, P. Giaccone University Hospital, Palermo, Italy.
² Pathology Section, Internal Medicine and Medical Specialties, P. Giaccone University Hospital, Palermo, Italy.
³ Rheumatology Section, Internal Medicine and Medical Specialties, P. Giaccone University Hospital, Palermo, Italy. giuliana.guggino@unipa.it.

PMID: 36622096
DOI: 10.55563/clinexprheumatol/oxy3ip

No abstract available

Publication types

Letter

MeSH terms

Anti-Asthmatic Agents*
Antibodies, Monoclonal, Humanized / therapeutic use
Eosinophilia* / drug therapy
Eosinophils
Humans
Receptors, Interleukin-5

Substances

benralizumab
Receptors, Interleukin-5
Antibodies, Monoclonal, Humanized
Anti-Asthmatic Agents

Supplementary concepts

Eosinophilic Fasciitis